2.
BRAF突变晚期NSCLC患者的靶向或免疫临床研究概况
Summary of clinical study of targeted treatment and immunotherapy for BRAF-mutant advanced NSCLC
| Number | Phase | Drugs | Target group | Line of treatment | BRAF mutations | N | Combined/Single | State | Targeted therapy/Immunotherapy |
| R: Ribociclib; A: Atezolizumab; P: Pembrolizumab; B: Binimetinib; C: Cobimetinib; BM: brain metastases. | |||||||||
| NCT03543306 | II | D+T | Metastatic NSCLC | ≥1 | BRAF V600E | 27 | Combined | Recruiting | Targeted therapy |
| NCT04302025 | II | V+C | Resectable phase II-III NSCLC | Neoadjuvant and Ajuvant | BRAF | 60 | Combined | Recruiting | Targeted therapy |
| NCT02974725 | Ib | LXH254+LTT462，LXH254+T，LXH254+R | NSCLC and Melanoma | ≥1 | BARF/KRAS/NARS | 331 | Combined | Recruiting | Targeted therapy |
| NCT04452877 | II | D+T | Metastatic NSCLC (Chinese) | 1-3 | BRAF V600E | 20 | Combined | Not yet recruiting | Targeted therapy |
| NCT02314481 | II | V | NSCLC | ≥1 | BRAF V600 | 119 | Single | Recruiting | Targeted therapy |
| NCT02276027 | II | MEK162 | Advanced NSCLC | ≥1 | BRAF/KRAS/NRAS | 66 | Single | Finished | Targeted therapy |
| NCT03178552 | II/III | A+C+V | Unresectable or Advanced NSCLC | 1 | BRAF V600 | 700 | Combined | Recruiting | Immune combined targeted therapy |
| NCT03049618 | IIa | P+sEphB4-HSA | Locally advanced or Advanced NSCLC | ≥2 | BRAF | 50 | Combined | Recruiting | Immunotherapy |
| NCT04543188 | Ia/b | ARRY461+B | NSCLC with or not with BM | ≥1 | BRAF V600 | 225 | Combined | Not yet recruiting | Targeted therapy |